Tasly Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Tasly Pharmaceutical Group Co Ltd (600535) has an Asset Resilience Ratio of 11.69% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 600535 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Tasly Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. See 600535 equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Tasly Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Tasly Pharmaceutical Group Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.83 Billion | 11.69% |
| Total Liquid Assets | CN¥1.83 Billion | 11.69% |
Asset Resilience Insights
- Moderate Liquidity: Tasly Pharmaceutical Group Co Ltd has 11.69% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Tasly Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tasly Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
Annual Asset Resilience Ratio for Tasly Pharmaceutical Group Co Ltd (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Tasly Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.09% | CN¥1.39 Billion ≈ $204.00 Million |
CN¥15.34 Billion ≈ $2.24 Billion |
+5.58pp |
| 2024-12-31 | 3.50% | CN¥524.72 Million ≈ $76.78 Million |
CN¥14.98 Billion ≈ $2.19 Billion |
+1.70pp |
| 2023-12-31 | 1.80% | CN¥300.71 Million ≈ $44.00 Million |
CN¥16.71 Billion ≈ $2.45 Billion |
-5.05pp |
| 2022-12-31 | 6.85% | CN¥1.12 Billion ≈ $164.62 Million |
CN¥16.43 Billion ≈ $2.40 Billion |
-2.15pp |
| 2021-12-31 | 8.99% | CN¥1.49 Billion ≈ $217.66 Million |
CN¥16.54 Billion ≈ $2.42 Billion |
+8.13pp |
| 2020-12-31 | 0.87% | CN¥142.92 Million ≈ $20.91 Million |
CN¥16.49 Billion ≈ $2.41 Billion |
+0.62pp |
| 2019-12-31 | 0.25% | CN¥59.39 Million ≈ $8.69 Million |
CN¥24.01 Billion ≈ $3.51 Billion |
-0.38pp |
| 2018-12-31 | 0.63% | CN¥158.30 Million ≈ $23.16 Million |
CN¥25.17 Billion ≈ $3.68 Billion |
-1.94pp |
| 2017-12-31 | 2.57% | CN¥552.66 Million ≈ $80.87 Million |
CN¥21.53 Billion ≈ $3.15 Billion |
+1.00pp |
| 2016-12-31 | 1.56% | CN¥267.90 Million ≈ $39.20 Million |
CN¥17.13 Billion ≈ $2.51 Billion |
-0.19pp |
| 2015-12-31 | 1.76% | CN¥270.50 Million ≈ $39.58 Million |
CN¥15.41 Billion ≈ $2.26 Billion |
+1.39pp |
| 2014-12-31 | 0.36% | CN¥46.85 Million ≈ $6.86 Million |
CN¥12.92 Billion ≈ $1.89 Billion |
-0.47pp |
| 2013-12-31 | 0.83% | CN¥84.96 Million ≈ $12.43 Million |
CN¥10.21 Billion ≈ $1.49 Billion |
+0.58pp |
| 2012-12-31 | 0.25% | CN¥19.00 Million ≈ $2.78 Million |
CN¥7.49 Billion ≈ $1.10 Billion |
-0.36pp |
| 2006-12-31 | 0.61% | CN¥20.04 Million ≈ $2.93 Million |
CN¥3.26 Billion ≈ $477.01 Million |
-2.66pp |
| 2005-12-31 | 3.27% | CN¥90.08 Million ≈ $13.18 Million |
CN¥2.75 Billion ≈ $403.06 Million |
+2.82pp |
| 2004-12-31 | 0.46% | CN¥10.02 Million ≈ $1.47 Million |
CN¥2.20 Billion ≈ $322.08 Million |
-- |
About Tasly Pharmaceutical Group Co Ltd
Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical… Read more